Literature DB >> 32091422

Understanding Opioid Use After Total Hip Arthroplasty: A Comprehensive Analysis of a Mandatory Prescription Drug Monitoring Program.

Timothy L Tan1, Alexander J Rondon, Zachary Wilt, William L Wang, Irene Kalbian, Carol Foltz, Pedro K Beredjiklian, William V Arnold.   

Abstract

INTRODUCTION: Opioids remain the most prescribed medication after total hip arthroplasty (THA) despite the potential for abuse and adverse effects. Given the high rates of opioid abuse and potential adverse effects, the reporting of controlled substances is now mandatory in many statewide databases. This study aimed to use a mandatory statewide database to analyze opioid prescription patterns in postoperative THA patients and identify independent risk factors for those patients who need a second prescription and/or require prolonged use (>6 months).
METHODS: We retrospectively reviewed a consecutive series of 619 primary THAs. Demographic and comorbidity information were collected for all patients. Narcotic prescription data (converted to morphine milligram equivalents) as well as prescription data for sedatives, benzodiazepines, and stimulants were collected from the State's Controlled Substance Monitoring websites 6 months before and 9 months after the index procedure. Bivariate and multivariate analyses were done for second prescription and continued use.
RESULTS: Of the 619 patients who underwent THA, 34.9% (216/619) used preoperative opioids, 36.2% (224/619) filled a second opioid prescription, and 10.5% (65/619) had continued use past 6 months. Patients with preoperative opioids were at an approximately 4-fold increased odds of requiring a second script and 12 times odds of continued opioid use. In the multivariate analysis, independent risk factors for requiring a second prescription, in descending order of magnitude, included the use of any sedative or sleep aid prescription and preoperative narcotic use. Independent risk factors for continued narcotic use longer than 6 months after THA included preoperative narcotic use and increased length of stay. DISCUSSION: Several risk factors and their relative weight have been identified for continued narcotic consumption after THA. It is important for surgeons to consider these predisposing factors preoperatively during the informed consent process and for managing postoperative pain expectations.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32091422     DOI: 10.5435/JAAOS-D-19-00676

Source DB:  PubMed          Journal:  J Am Acad Orthop Surg        ISSN: 1067-151X            Impact factor:   3.020


  5 in total

Review 1.  Opioid Use Consequences, Governmental Strategies, and Alternative Pain Control Techniques Following Total Hip Arthroplasties.

Authors:  Kevin Berardino; Austin H Carroll; Daniel Popovsky; Robert Ricotti; Matthew D Civilette; William F Sherman; Alan D Kaye
Journal:  Orthop Rev (Pavia)       Date:  2022-05-31

2.  Factors Associated With Increasing Length of Stay for Rheumatoid Arthritis Patients Undergoing Total Hip Arthroplasty and Total Knee Arthroplasty.

Authors:  Kyle W Morse; Nicole K Heinz; Jeremy M Abolade; Joshua Wright-Chisem; Linda Alice Russell; Meng Zhang; Serene Mirza; Diyu Pearce-Fisher; Dana E Orange; Mark P Figgie; Peter K Sculco; Susan M Goodman
Journal:  HSS J       Date:  2022-02-22

3.  Pre-emptive analgesia with methylprednisolone and gabapentin in total knee arthroplasty in the elderly.

Authors:  Henryk Liszka; Małgorzata Zając; Artur Gądek
Journal:  Sci Rep       Date:  2022-02-11       Impact factor: 4.379

4.  Preoperative Opioid Use Results in Greater Postoperative Opioid Consumption After Thumb Basal Joint Arthroplasty.

Authors:  Alexander J Adams; Joseph Paladino; Clay Townsend; Asif M Ilyas
Journal:  J Hand Surg Glob Online       Date:  2022-01-10

5.  Nonsurgical Providers Provide the Majority of Postoperative Opioid Prescriptions After Hand Surgery.

Authors:  Madeline Tadley; Clay B Townsend; Shivangi Bhatt; Monica Morgenstern; Kevin F Lutsky; Pedro K Beredjiklian
Journal:  Cureus       Date:  2021-06-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.